nach oben

Drugs & Aging

Erschienen in:

01.11.2015 | Leading Article

Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope

verfasst von: Valentin Goede, Michael Hallek

Erschienen in: Drugs & Aging | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Chronic lymphocytic leukaemia (CLL) is mostly considered a disease of the elderly. As such, many patients present with comorbidities. Several scores allow for a qualitative and quantitative assessment of comorbidity in patients with CLL. Although our knowledge about the impact of comorbidity on outcomes in patients with CLL is still incomplete, it is becoming increasingly apparent that comorbidities could negatively interfere with CLL treatment. Recently, a number of new agents have been approved for use in patients with previously untreated CLL and comorbidities (i.e. obinutuzumab, ofatumumab), as well as in patients with previously treated or high-risk CLL (i.e. idelalisib, ibrutinib). This review discusses the role of comorbidity in patients with CLL, together with the changing treatment landscape for CLL in this patient population.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.PubMedCentralCrossRefPubMed

Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36(4):453–71.CrossRefPubMed

Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41(3):237–48.CrossRefPubMed

Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatrics Soc. 1995;43(2):130–7.CrossRef

Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, et al. A manual of guidelines to score the Modified Cumulative Illness Rating Scale and its validation in acute hospitalized elderly patients. J Am Geriatrics Soc. 2008;56(10):1926–31.CrossRef

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.CrossRefPubMed

Mulligan SP, Gill D, Turner P, Renwick WEP, Latimer M, Mackinlay N, et al. A randomised dose de-escalation study of oral fludarabine, ±oral cyclophosphamide and intravenous rituximab as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years: final analysis of response and toxicity. Blood. 2014;124:4695.

Eichhorst B, Fink AM, Busch R, Kovacs G, Maurer C, Lange E, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia. Blood. 2014;124:19.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.CrossRefPubMed

10.

Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.PubMedCentralCrossRefPubMed

11.

Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99(6):1095–100.PubMedCentralCrossRefPubMed

12.

Goede V, Raymonde B, Stilgenbauer S, Winter E, Fink A-M, Fischer K, et al. Cumulative Illness Rating Scale (CIRS) is a valuable tool to assess and weigh comorbidity in patients with chronic lymphocytic leukemia: results from the CLL8 trial of the German CLL Study Group. Haematologica. 2012;97(S1):154.

13.

Reyes C, Satram-Hoang S, Hoang K, Momin F, Guduru SR, Skettino S. What is the impact of comorbidity burden on treatment patterns and outcomes in elderly chronic lymphocytic leukemia patients? Blood. 2012;120(21):758.

14.

Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49–56.CrossRefPubMed

15.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF et al. SEER cancer statistics review, 1975–2009 (vintage 2009 populations). National Cancer Institute. 2012. http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 29 Sept 2015.

16.

Yancik R. Epidemiology of cancer in the elderly: current status and projections for the future. Rays. 1997;22(1 Suppl):3–9.PubMed

17.

Baumann T, Delgado J, Santacruz R, Martinez-Trillos A, Royo C, Navarro A, et al. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica. 2014;99(10):1599–604.PubMedCentralCrossRefPubMed

18.

Manda S, James S, Wang R, Krishnan R, Danilov AV. Impact of comorbidities on treatment outcomes in chronic lymphocytic leukemia: a retrospective analysis. Blood. 2014;124:1312.CrossRef

19.

Michallet M, Cazin B, Bouvet E, Oberic L, Schlaifer D, Mosser L, et al. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. J Geriatrics Oncol. 2013;4(2):141–7.CrossRef

20.

Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukemia (COMPLEMENT1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873–83.CrossRefPubMed

21.

Mulligan SP, Gill D, Turner P, Renwick WEP, Latimer M, Mackinlay N, et al. Toxicity is not associated with age or comorbidity score in a randomised study of oral fludarabine and cyclophosphamide and IV rituximab (FCR) as first-line therapy of fit, elderly patients with chronic lymphocytic leukemia (CLL). Blood. 2013;122:528.

22.

Lichtman SM, Etcubanas E, Budman DR, Eisenberg P, Zervos G, D’Amico P, et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest. 2002;20(7–8):904–13.CrossRefPubMed

23.

Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol. 2002;50(1):37–45.CrossRefPubMed

24.

Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–65.CrossRefPubMed

25.

Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109(11):2291–8.CrossRefPubMed

26.

Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long term results of the fludarabine, cyclophosphamide & rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975–80.PubMedCentralCrossRefPubMed

27.

Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012;119(13):3184–5.CrossRefPubMed

28.

Smolej L, Brychtova Y, Doubek M, Cmunt E, Spacek M, Belada D, et al. Low-dose FCR is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Updated results of Project Q-Lite by Czech CLL Study Group. Blood. 2014;124:4670.

29.

Bouvet E, Borel C, Oberic L, Compaci G, Cazin B, Michallet AS, et al. Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. Haematologica. 2013;98(1):65–70.PubMedCentralCrossRefPubMed

30.

Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, et al. Efficacy and safety of frontline therapy with “FCR” regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli Chronic Lymphocytic Leukemia Study Group experience. Haematologica. 2015;100(5):662–9.PubMedCentralCrossRefPubMed

31.

Leblond V, Laribi K, Ilhan O, Aktan M, Unal A, Rassam SMB, et al. Rituximab in combination with bendamustine or chlorambucil for treating patients with chronic lymphocytic leukemia: interim results of a phase IIIb study (MaBLe). Blood. 2012;120(21):2744.

32.

Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382–91.CrossRefPubMed

33.

Woyach JA, Ruppert AS, Rai K, Lin TS, Geyer S, Kolitz J, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol. 2013;31(4):440–7.PubMedCentralCrossRefPubMed

34.

Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32(12):1236–41.CrossRefPubMed

35.

Foa R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014;89(5):480–6.CrossRefPubMed

36.

Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015. doi:10.1038/leu.2015.14.PubMed

37.

Gupta IV, Jewell RC. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann N Y Acad Sci. 2012;1263:43–56.CrossRefPubMed

38.

Nightingale G. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann Pharmacother. 2011;45(10):1248–55.CrossRefPubMed

39.

Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749–55.CrossRefPubMed

40.

Offner F, Panagiotidis P, Afanasiev BV, Janssens A, Grosicki S, Homeda W, et al. Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB115991. Leuk Lymphoma. 2013;4:29.

41.

Illidge T, Cheadle EJ, Donaghy C, Honeychurch J. Update on obinutuzumab in the treatment of B-cell malignancies. Expert Opin Biol Ther. 2014;14(10):1507–17.CrossRefPubMed

42.

Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22–33.PubMedCentralCrossRefPubMed

43.

Flynn JM, Byrd JC, Kipps TJ, Boxer M, Kolibaba KS, Tyson N, et al. Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GAO4768g) trial. J Clin Oncol. 2014;32(5s):7083.

44.

Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124(14):2196–202.CrossRefPubMed

45.

ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia—focus on the B-cell receptor. Clin Cancer Res. 2014;20(3):548–56.CrossRefPubMed

46.

Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175–84.PubMedCentralCrossRefPubMed

47.

Burger JA, Okkenhaug K. Haematological cancer: idelalisib-targeting PI3Kdelta in patients with B-cell malignancies. Nat Rev Clin Oncol. 2014;11(4):184–6.PubMedCentralCrossRefPubMed

48.

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390–7.PubMedCentralCrossRefPubMed

49.

O’Brien S, Lamanna N, Kipps TJ, Flinn IW, Zelenetz AD, Burger JA, et al. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood. 2014;124:1994.

50.

Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 2014;10(6):957–67.PubMedCentralCrossRefPubMed

51.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.PubMedCentralCrossRefPubMed

52.

O’Brien S, Jones JA, Coutre S, Mato AR, Hillmen P, Tam C, et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial. Blood. 2014;124(21):327.

53.

Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.PubMedCentralCrossRefPubMed

54.

O’Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48–58.PubMedCentralCrossRefPubMed

55.

Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Puvvada S, et al. ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control. J Clin Oncol. 2014;32(15s):7015.

56.

Roberts AW, Ma S, Brander DM, Kipps TJ, Barrientos JC, Davids MS, et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood. 2014;124(21):325.

57.

Flinn I, Brunvand M, Dyer MJS, Hillman P, Jones J, Lymp J, et al. Preliminary results of a phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood. 2014;124(21):4687.

Titel: Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope
verfasst von: Valentin Goede
Michael Hallek
Publikationsdatum: 01.11.2015
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 11/2015
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-015-0308-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2015

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly

Best Practices for Drug Prescribing in Older Adults: A Call for Action

Erratum to: Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United States

Nurse Education to Reduce Harmful Medication Use in Assisted Living Facilities: Effects of a Randomized Controlled Trial on Falls and Cognition

Antihypertensive Medications, Loop Diuretics, and Risk of Hip Fracture in the Elderly: A Population-Based Cohort Study of 81,617 Italian Patients Newly Treated Between 2005 and 2009